BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rezasoltani S, Yadegar A, Asadzadeh Aghdaei H, Reza Zali M. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors. Cancer Med 2021;10:1141-54. [PMID: 33369247 DOI: 10.1002/cam4.3694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Borella F, Carosso AR, Cosma S, Preti M, Collemi G, Cassoni P, Bertero L, Benedetto C. Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions. ACS Infect Dis 2021;7:987-1009. [PMID: 33848139 DOI: 10.1021/acsinfecdis.0c00839] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
2 Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Seminars in Cancer Biology 2021;73:356-76. [DOI: 10.1016/j.semcancer.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Oh B, Boyle F, Pavlakis N, Clarke S, Eade T, Hruby G, Lamoury G, Carroll S, Morgia M, Kneebone A, Stevens M, Liu W, Corless B, Molloy M, Kong B, Libermann T, Rosenthal D, Back M. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy? Cancers (Basel) 2021;13:4824. [PMID: 34638308 DOI: 10.3390/cancers13194824] [Reference Citation Analysis]
4 Roviello G, Iannone LF, Bersanelli M, Mini E, Catalano M. The gut microbiome and efficacy of cancer immunotherapy. Pharmacol Ther 2021;:107973. [PMID: 34453999 DOI: 10.1016/j.pharmthera.2021.107973] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhang X, Li H, Lv X, Hu L, Li W, Zi M, He Y. Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors. Life 2022;12:409. [DOI: 10.3390/life12030409] [Reference Citation Analysis]
6 Sammallahti H, Kokkola A, Rezasoltani S, Ghanbari R, Asadzadeh Aghdaei H, Knuutila S, Puolakkainen P, Sarhadi VK. Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients. Int J Mol Sci 2021;22:12978. [PMID: 34884776 DOI: 10.3390/ijms222312978] [Reference Citation Analysis]
7 Lin Y, Kong D, Zhang Y. Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy? Front Oncol 2022;12:852194. [DOI: 10.3389/fonc.2022.852194] [Reference Citation Analysis]
8 Li Y, Wang S, Lin M, Hou C, Li C, Li G. Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. Front Med 2022. [PMID: 35648368 DOI: 10.1007/s11684-022-0927-0] [Reference Citation Analysis]
9 Zhou Y, Liu Z, Chen T. Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. Front Oncol 2022;12:847350. [PMID: 35252014 DOI: 10.3389/fonc.2022.847350] [Reference Citation Analysis]